Improved in vivo targeting of BCL-2 phenotypic conversion through hollow gold nanoshell delivery
- 87 Downloads
Although new cancer therapeutics are discovered at a rapid pace, lack of effective means of delivery and cancer chemoresistance thwart many of the promising therapeutics. We demonstrate a method that confronts both of these issues with the light-activated delivery of a Bcl-2 functional converting peptide, NuBCP-9, using hollow gold nanoshells. This approach has shown not only to increase the efficacy of the peptide 30-fold in vitro but also has shown to reduce paclitaxel resistant H460 lung xenograft tumor growth by 56.4%.
KeywordsPeptide delivery Bcl-2 Hollow gold nanoshells Apoptosis Resistant cancer NuBCP
This work was supported by the National Institutes of Health (NIH) Grant R01 EB012637 and in part by Grants from the US Army Medical Research and Material Command (W81XWH-08-1-0600 and W81XWH-12-1-0069), American Cancer Society (RSG-13-132-01-CDD), National Institutes of Health (5RO1ES016651) and Oregon State University Venture Development Fund (http://advantage.oregonstate.edu/funding-opportunities). The authors thank support of the NRI Microscopy Center, the Olympus confocal microscope was funded by the NIH Grant 1S10RR022585-01A1. The authors thank A. Mikhailovsky for helpful conversations and aid of the UCSB Optical Characterization Facility. The ultrafast laser system was funded by DURIP ARO Grant 66886LSRIP. The authors would also like to thank former graduate student Demosthenes Morales for helpful discussions.
Compliance with ethical standards
Conflict of interest
The authors declare no competing financial interests.
- 9.Bouchalova K, Svoboda M, Kharaishvili G, Vrbkova J, Bouchal J, Trojanec R et al (2015) BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. Tumour Biol J Int Soc Oncodev Biol Med 36(6):4243–4252CrossRefGoogle Scholar
- 18.Huang S, Jiang C, Guo H, Wang J, Liu Y, Li C, Lopez E, Zhang H, Lorence EA, Merolle M et al (2017) Resistance mechanisms underlying venetoclax resistance in mantle cell lymphoma. Blood 130(Suppl 1):2749Google Scholar